Understanding, tracking and eliminating malaria transmission in the Asia - Pacific Region
Project Number1U19AI129392-01
Contact PI/Project LeaderMUELLER, IVO J
Awardee OrganizationINSTITUT PASTEUR
Description
Abstract Text
Summary
As the Asia-Pacific aim to eliminate malaria from the entire region by 2030, a number of key challenges related
to increasing strong variations in malaria transmission, the presence of a large reservoir of infected but
asymptomatic individual and the development of resistance to frontline antimalarial treatment need to be
confronted. In addition, the predominance of P. vivax infections in the region results in the particular challenge
of dealing with P. vivax hypnozoites and the relapsing infections the cause. The Asia-Pacific ICEMR project is
proposing to conduct coordinated set of field and in-depth biological studies in 3 sites in Cambodia, Papua
New Guinea and Thailand that span the range of transmission intensities currently found in the Asia-Pacific
regions. In the Epidemiology Project spatio-temporal patterns of risk of malaria infection and disease will be
investigate through a combination of large cross-sectional and longitudinal cohort studies that combine
excellent epidemiological study designs with state-of-the-art molecular detection and genotyping of
Plasmodium spp. infections and an assessment of host immune responses and their link to exposure and
clinical protection. The information thus gained will be used to evaluate improved surveillance strategies
through an innovative combination of computer simulations and field application. The Transmission Project
will use direct membrane feeding assay as a xenodiagnostic tool to determine the infective reservoir as each
site and investigate host, parasite and host factors that contribute to sustaining endemic transmission at each
site. In addition, we will study patterns of human-vector contact in low transmission settings by investigating
human antibodies to anopheline salivary protein as marker exposure to mosquito bites. A key question in both
studies is how artemisinin and partner drug resistance affects parasite fitness both in chronic asymptomatic
infections and transmissibility. Finally, the P. vivax Relapse Project will specifically address the role of
relapsing infections from long-lasting liver stages in the increased resilience of P. vivax against control and
elimination. The conduct of these studies will use spatially explicit malaria transmission models, next-
generation sequencing (NGS)-based high-throughput genotyping methods and a range of high-throughput and
functional assay of humoral immune responses that will be developed in 3 resource cores. These
interconnected, multi-disciplinary studies thus aim to identify and characterize critical steps in malaria
transmission cycle and thereby gain a better understanding of parasite, host and vector factors that contribute
to continued transmission in the context of intensive national malaria control and elimination programs. This
knowledge will assist in the development of novel approaches to target residual transmission pockets.
Public Health Relevance Statement
Narrative
Eliminating malaria from the Asia-Pacific will be made much easier if countries have a good understanding not
only where people with malaria infections and disease are living but also where they may have acquired
infections and who could infect new mosquito and thus pass the infection on to other people. With a
coordinated of epidemiological and vector studies in Thailand, Cambodia, and Papua New Guinea, that span
the different levels of malaria transmission in the Asia-Pacific, we will now determine the key reasons where
and when people acquire infection and how likely they are to pass it on to other people. This information will
help design better ways to identify village and population groups at the highest risk of malaria
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
278151154
UEI
JRDEJNVPC8T3
Project Start Date
28-April-2017
Project End Date
31-March-2024
Budget Start Date
28-April-2017
Budget End Date
31-March-2018
Project Funding Information for 2017
Total Funding
$690,181
Direct Costs
$639,649
Indirect Costs
$50,532
Year
Funding IC
FY Total Cost by IC
2017
National Institute of Allergy and Infectious Diseases
$690,181
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1U19AI129392-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U19AI129392-01
Patents
No Patents information available for 1U19AI129392-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U19AI129392-01
Clinical Studies
No Clinical Studies information available for 1U19AI129392-01
News and More
Related News Releases
No news release information available for 1U19AI129392-01
History
No Historical information available for 1U19AI129392-01
Similar Projects
No Similar Projects information available for 1U19AI129392-01